Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population

The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.

The investigators intend to test Epstein-Barr virus antibodies (Viral Capsid Antigen-immunoglobulin A， Epstein-Barr nuclear antigen 1-immunoglobulin A， early antigen-immunoglobulin A， Zta-immunoglobulin A， Rta-immunoglobulin G, Bnlf 2b) by ELISA and Epstein-Barr virus DNA by quantitative polymerase chain reaction, target sequencing and CRISPR-associated protein 12a in nasopharyngeal brushing and plasma of the same population at high-risk of nasopharyngeal carcinoma so as to determine the best method in nasopharyngeal carcinoma screening.

Inclusion Criteria:

• residents in Southern China
• 30-62 years old
• male
• a first-degree relative of at least one nasopharyngeal carcinoma patient
• no medical record of nasopharyngeal carcinoma
• Eastern Cooperative Oncology Group score of 0-2
• be able to comprehend, sign, and date the written informed consent document to participate in the study

Exclusion Criteria:

• history of nasopharyngeal carcinoma
• heavy cardiovascular, liver or kidney disease
• on systemic steroid or immunosuppressant treatment or active autoimmune disease